Addex Pharmaceuticals Ltd. (ADXN.SW)
-Swiss 6.61 
0.06(0.92%) 10:31AM EDT
| Prev Close: | 6.55 |
|---|
| Open: | 6.74 |
|---|
| Bid: | 6.61 |
|---|
| Ask: | 6.69 |
|---|
| 1y Target Est: | 14.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 6.61 - 6.80 |
|---|
| 52wk Range: | 6.15 - 12.50 |
|---|
| Volume: | 13,169 |
|---|
| Avg Vol (3m): | 14,224 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CHF.
Headlines
- Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441Thomson Reuters ONE(Tue 1:33AM EDT)
- Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET StudyThomson Reuters ONE(Wed, May 1)
- Addex Announces CFO, Tim Dyer, to Transition to External Consulting RoleThomson Reuters ONE(Tue, Apr 30)
- Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol DependenceThomson Reuters ONE(Tue, Apr 30)
- Addex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441Thomson Reuters ONE(Wed, Apr 24)
- Addex Announces Issuance of a Broad European Composition of Matter Patent for DipraglurantThomson Reuters ONE(Mon, Apr 22)
- Swiss stocks - Factors to watch on April 18at Reuters(Thu, Apr 18)
- Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)Thomson Reuters ONE(Thu, Apr 18)
- Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)Thomson Reuters ONE(Thu, Mar 21)
- Addex Shareholders Approve All Board Proposals at Annual General MeetingThomson Reuters ONE(Wed, Mar 20)
- Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's ResearchThomson Reuters ONE(Tue, Mar 19)
- Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A ReceptorThomson Reuters ONE(Mon, Mar 4)
- Addex Therapeutics Reports 2012 Financial ResultsThomson Reuters ONE(Thu, Feb 28)
- ADXN - What Lilly's Failure Means For AddexZacks Small Cap Research(Wed, Aug 29)
- ADXN - Get To Know Addex Therapeutics - Initiating CoverageZacks Small Cap Research(Wed, Jun 20)
Reports
- No Reports available for ADXN.SW at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-11)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forADXN.SW.